Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kirin, Amgen Wind Up Drug Development Joint Venture
November 2, 2017
- EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma
November 2, 2017
- Mitsubishi Tanabe’s HIF-PH Inhibitor Enters Japan PIII
November 2, 2017
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai’s Half-Year Sales Grow on Global Brands, Profits Slide after EA Pharma One-Off Gain
November 2, 2017
- Mitsubishi Tanabe’s Half-Year Sales Up 4.5%, but Profits Dip on Radicava Promotion Costs
November 2, 2017
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Astellas Delivers Positive Data in 1st HIF-PH Inhibitor Study in Japan
November 1, 2017
- Aspen Takes Over Arixtra from GSK, Transfer Pact Completed in Japan
November 1, 2017
- Bristol-Myers France’s Barland to Become Japan President
November 1, 2017
- Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
November 1, 2017
- Daiichi Sankyo Shooting for Top Share for Lixiana by Tokyo Olympics: President
November 1, 2017
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Micardis Generic Penetration “Faster than Expected”: Astellas President
November 1, 2017
- Towa to Discontinue Sales of 34 Products due to Bulk Drug Supply Problems, Weak Demand
November 1, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Parkinson’s Disease Therapy Rasagiline Improves Average Daily Off-Time in Japan PII/PIII Study: Takeda
November 1, 2017
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…